Zilbrysq

PreclinicalSmall molecule

CCentre Hospitalier Universitaire de Nice

Zilbrysq is one of 26 small molecule programs targeting Myasthenia Gravis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myasthenia GravisActive, not recruiting

Myasthenia GravisPreclinical

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Myasthenia Gravis

#DrugCompanyPhaseTrials

Ultomiris

AstraZeneca

Approved

4 2

Vyvgart

Argenx

Approved

13 3

Rysodeg

UCB

Approved

2 4

Rituxan

Roche

Phase 3

7 5

Rayos

RRoxane Laboratories

Approved

—6

Proair HFA

GGlaxo Dba Glaxosmithkline

Fabhalta

3 8

Blincyto

Amgen

Phase 3

2 9

Actemra

CCelltrion

Phase 3

2 10

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myasthenia Gravis1 trial

Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months

Recruiting·—··NCT06815133·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zilbrysq. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zilbrysq compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zilbrysq. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Hospitalier Universitaire de Nice company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCentre Hospitalier Universitaire de Nice

Zilbrysq

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News